Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the first ...
Dr. Todd Rosengart, professor and chair of the Michael E. DeBakey Department of Surgery at Baylor College of Medicine, has ...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of one ...
MedPage Today on MSN
For Your Patients: What to Know About the Newest Treatments for HR+/HER2- Breast Cancer
The first-line standard of care for HR-positive/HER2-negative breast cancer is cyclin-dependent kinase (CDK)4/6 inhibitors ...
This immunotherapy treatment holds promise beyond rectal cancer. In early studies of people with esophageal, bladder, or ...
In 1989, one month after she got engaged, Koreen Burrow learned she has multiple sclerosis. Over the past 36 years, the ...
Some experts believe the cancer label can be inappropriate for certain low-risk conditions and advocate dropping the C-word.
Dr. Todd Rosengart, professor and chair of the Michael E. DeBakey Department of Surgery at Baylor College of Medicine, has ...
Axolotls can regenerate optic nerves, retinas, and parts of their brain. Provost's Undergraduate Research Award-winner Ted ...
Discover how Aga Khan University Hospital tackles doctor migration in Africa with competitive pay, world-class equipment, and ...
During a live event, Jan Drappatz, MD, surveyed participants on the rationale for their choice of treatment for a 39-year-old patient with grade 2 astrocytoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback